Sveriges mest populära poddar

BiotechTV - News

Vetenskap Life Science

ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs

35 min•31 maj 2026

The lead two programs, which target TLR7/8 and PARP1, have data at ASCO and were licensed with the idea of laying the foundation for clinical expertise at Eikon. Another clinical program, a WRN helicase inhibitor, is the first to entirely come out of Eikon's platform. Plus, Dr. Perlmutter's take on being a public company, and his thoughts on China as a medicine cabinet to the world.

Fler avsnitt av BiotechTV - News

ASCO 2026: "The results that we presented from the RASolute 302 trial are unprecedented." - The CEO behind this year's pancreatic cancer breakthrough walks us through the full results and implications

31 maj•13 min

London based Cytospire Therapeutics has announced an $83M series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors

Replimune's Chairman discusses FDA's polarizing decision to not approve the company's melanoma treatment after a new review. He says they have filed a FOIA request to learn more about FDA's process

22 apr.•23 min

Invivyd develops monoclonal antibodies to prevent or treat infectious diseases. This approach could be useful in tamping down the measles outbreaks that have been occurring due to under-vaccination

22 apr.•23 min

Bay Area based Epia Neuro exited stealth earlier this month with the goal of developing a device implanted in the skull that could act as an interface to a glove to helps stroke survivors regain grip

21 apr.•17 min

Peter Hotez discusses tropical disease, the importance of science communication, career advice for young scientists, and more

21 apr.•42 min

Physican and Biotech Investor Adam May reacts to this morning's 52 week Rezpeg data in alopecia from Nektar

20 apr.•14 min

10x Genomics today is announcing Atera, its new in situ spatial transcriptomics platform

19 apr.•14 min

Is this analyst the world's biggest bear on the weight loss space? After downgrading Lilly to a sell rating, HSBC's Rajesh Kumar discusses why he thinks pricing factors are being under-appreciated

17 apr.•26 min

Raymond James Biotech Innovation Symposium: Biotech analyst Tiago Fauth shares his read on the mood of investors and discusses companies he covers

14 apr.•9 min

BiotechTV - News med BiotechTV finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.